| 1.12 0.09 (8.74%) | 11-06 12:17 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.43  |
1-year : | 1.68 |
| Resists | First : | 1.22 |
Second : | 1.44 |
| Pivot price | 1.05 |
|||
| Supports | First : | 0.88 | Second : | 0.73 |
| MAs | MA(5) : | 1.08 |
MA(20) : | 1.06 |
| MA(100) : | 2.31 |
MA(250) : | 3.29 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 56.5 |
D(3) : | 55 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 5.44 | Low : | 0.88 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CLLS ] has closed below upper band by 31.9%. Bollinger Bands are 58.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.16 |
| Low: | 0.99 - 0.99 | 0.99 - 1 |
| Close: | 1.02 - 1.03 | 1.03 - 1.04 |
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
Fri, 06 Nov 2026
Cellectis (CLLS) Set to Release Earnings on Friday - MarketBeat
Thu, 05 Nov 2026
Cellectis S.A. (CLLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 04 Nov 2026
Cellectis S.A. (CLLS) stock price, news, quote and history - Yahoo Finance Singapore
Tue, 03 Nov 2026
Cellectis S.A. (CLLS) Seasonal returns chart - Yahoo Finance - Yahoo Finance Singapore
Sun, 25 Oct 2026
Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Target Price of $5.46 According to Analysts - MarketBeat
Thu, 15 Oct 2026
Securities Fraud Investigation Into Cellectis S.A. (CLLS) - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 73 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 13.4 (%) |
| Shares Short | 351 (K) |
| Shares Short P.Month | 290 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.56 |
| Profit Margin | -102.4 % |
| Operating Margin | -340.7 % |
| Return on Assets (ttm) | -11.7 % |
| Return on Equity (ttm) | -94.6 % |
| Qtrly Rev. Growth | -62.1 % |
| Gross Profit (p.s.) | 0.87 |
| Sales Per Share | 0.87 |
| EBITDA (p.s.) | -0.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | 108 (M) |
| PE Ratio | -1.75 |
| PEG Ratio | 0 |
| Price to Book value | 2 |
| Price to Sales | 1.27 |
| Price to Cash Flow | -1.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|